American pharma company Viatris to sell certain businesses for $3.4bn
The drugmaker has received offer for its OTC business, and has agreed to divest its women's healthcare business,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
03 Oct 23
The drugmaker has received offer for its OTC business, and has agreed to divest its women's healthcare business,…
27 Sep 23
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS (omaveloxolone), the first and only FDA…
22 Sep 23
The deal will enable Glenmark Pharma to concentrate on its line of branded drugs for the treatment of…
22 Sep 23
The flagship product of Paratek Pharmaceuticals is Nuzyra (omadacycline), an oral and intravenous antibiotic approved for use in…
22 Sep 23
The merged entity will initially focus to advance Cyclo’s Phase 3 global TransportNPC study that is evaluating investigational…
11 Sep 23
Clinical-stage product candidates, casdozokitug and CHS-114, significantly advance next-generation immuno-oncology portfolio focused on the tumor microenvironment
07 Sep 23
The transaction is poised to accelerate NextGen Healthcare's growth and innovation, reinforcing its position as a trusted advisor…
06 Sep 23
As per the terms of the agreement announced in July, Travere Therapeutics remains entitled to receive potential milestone…
05 Sep 23
This is a strategic acquisition for Cipla South Africa to unlock the future growth opportunities and leverage cost…
29 Aug 23
Upon completion of the transaction, Thorne will transition into a privately held entity, and its common stock shares…